Madhuri Wadehra to Gene Expression Regulation, Neoplastic
This is a "connection" page, showing publications Madhuri Wadehra has written about Gene Expression Regulation, Neoplastic.
Connection Strength
2.171
-
Mah V, Elshimali Y, Chu A, Moatamed NA, Uzzell JP, Tsui J, Schettler S, Shakeri H, Wadehra M. ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas. Sci Rep. 2021 06 07; 11(1):11949.
Score: 0.546
-
Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695.
Score: 0.508
-
Kiyohara MH, Dillard C, Tsui J, Kim SR, Lu J, Sachdev D, Goodglick L, Tong M, Torous VF, Aryasomayajula C, Wang W, Najafzadeh P, Gordon LK, Braun J, McDermott S, Wicha MS, Wadehra M. EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene. 2017 10 19; 36(42):5793-5807.
Score: 0.414
-
Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, Braun J, Gordon LK, Wadehra M. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017 Aug; 134(1):29-40.
Score: 0.414
-
Patel KS, Kejriwal S, Sun MM, Thammachantha S, Duong C, Chan A, Cherian N, Romiyo P, Gordon LK, Yong W, Wadehra M, Yang I. Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma. J Neurooncol. 2020 Mar; 147(1):15-24.
Score: 0.124
-
Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J Biol Chem. 2014 May 16; 289(20):13974-85.
Score: 0.083
-
Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014 Apr; 13(4):902-15.
Score: 0.082